Canadian Sec - Delayed Quote CAD

Psyence Group Inc. (PSYG.CN)

0.0300

0.0000

(0.00%)

At close: April 22 at 3:43 PM EDT

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that its Australian subsidiary, Psyence Australia Pty Ltd ("Psyence Australia"), has entered into a partnership with Fluence, a global leader in profess

GlobeNewswire 8 days ago

PBM

PBMWW

PSYGF
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence" or the "Company") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the "Transaction"), Psyence is pleased to announce that the conditions to implement the Transaction have been met and that the Transaction has closed. Psyence has built a network of potential clients and customers, and successfully and lawfully distribut

GlobeNewswire 29 days ago

PSYGF

PBM

PBMWW
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ:PBM) ("PBM" or "Psyence Biomed") has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. T

GlobeNewswire last month

PSYGF

PBM

PBMWW
Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

TORONTO, March 11, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence Group" or the "Company") (CSE:PSYG) of the closing (the "Closing") of the business combination of its subsidiary, Psyence Biomedical Ltd ("PBM") (NASDAQ:PBM) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company, (the "Business Combination" or "Spin-Out") and the subsequent listing of PBM on the NASDAQ stock exchange with the trading symbol "PBM", Psyence Group prov

GlobeNewswire last month

PSYGF

PBM

PBMWW
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is excited to announce the completion of its subsidiary Psyence Biomedical Ltd’s (“Psyence Biomed”) merger (the “Business Combination”) with Newcourt Acquisition Corp ("Newcourt"), a special purpose acquisition company. The Business Combination will list Psyence Biomed on the NASDAQ stoc

GlobeNewswire 2 months ago

PSYGF
Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, today announced that its subsidiary, Psyence Biomedical Ltd ("Pubco"), has entered into a definitive securities purchase agreement (the "Securities Purchase Agreement") providing for up to US$10 million in funding through the issuance of up to four senior secured convertible n

GlobeNewswire 3 months ago

NCAC

NCACU

NCACW
Psyence Group Announces Resignation of Board Member

TORONTO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG) (“Psyence” or the “Company”), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing announced today that Mr. Marvin Singer has resigned from his position as a Non-Executive Director for personal reasons. Mr. Singer has been an integral part of the board of the Company since listing in January 2021, providing valuable insights and guidance during hi

GlobeNewswire 5 months ago

PSYGF
Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

TORONTO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration statement on Form F-4 (the “Registration Statement”), filed by Psyence Biomedical Ltd. (“Pubco”) with the Securities and Exchange Commission (“SEC”

GlobeNewswire 5 months ago

PSYGF

NCAC

NCACU
Psyence Production Expands Capability

TORONTO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence Production is a division of Psyence that oversees its psilocybin cultivation and production facility. Psyence operates one of the first government licensed commercial psilocybin production facilities in the w

GlobeNewswire 5 months ago

PSYGF
Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773. In connection with this issuance, the Company also issued 17,691 common shares a price of CAD$0.12 per common share as payment of a finder's f

GlobeNewswire 7 months ago

PSYGF
Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) today announced the entry into an amended and restated business combination agreement (the “Amended and Restated Business Combination Agreement”),

GlobeNewswire 8 months ago

NCAC

NCACU

PSYGF
Psyence Group Corporate Update

Highlights: Drug development, Phase IIb clinical trial advanced planning underway in AustraliaPsyence granted worldwide licensing agreement to commercialize Filament’s PEX010 (25 mg) in palliative care with exclusivity in key marketsSuccessful completion of exports of medical grade psilocybin mushrooms to three key global marketsExtraction capabilities enhanced at Psyence’s production facilityChristopher Bull appointed to the board of directors to drive Psyence’s intellectual property strategy T

GlobeNewswire 9 months ago

PSYGF
Psyence Appoints Intellectual Property Expert to Its Board of Directors

TORONTO, July 11, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to announce the appointment of Christopher Bull to the board of directors of the Company effective immediately. Mr. Bull is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional®. Over his 30-year career Mr. Bull has been an investor, director, founder, and advisor to a range of successful companies in Europe and North America wi

GlobeNewswire 9 months ago

PSYGF

Performance Overview

Return	PSYG.CN	S&P/TSX Composite index
YTD	-40.00%	+4.37%
1-Year	-73.91%	+5.70%
3-Year	-90.00%	+14.51%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Psyence Group Inc. (PSYG.CN)

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study

Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

Psyence Group Announces Resignation of Board Member

Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

Psyence Production Expands Capability

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

Psyence Group Corporate Update

Psyence Appoints Intellectual Property Expert to Its Board of Directors

Performance Overview